ClinicalTrials.Veeva

Menu

Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome

A

Ain Shams University

Status and phase

Completed
Phase 2

Conditions

Assisted Reproduction

Treatments

Drug: Cetrorelix

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Efficacy of the use of GnRH antagonist in treatment of those who develop early-onset severe ovarian hyperstimulation syndrome and had cancelled embryo transfer

Enrollment

84 patients

Sex

Female

Ages

20 to 42 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Women who develop early-onset severe ovarian hyperstimulation syndrome after controlled ovarian stimulation using long GnRH agonist protocol and hCG for triggering ovulation.

Exclusion criteria

  • Women on short or antagonist protocols.
  • Women who received GnRH agonist for triggering ovulation.
  • Women who had embryo transfer.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

84 participants in 2 patient groups

GnRHant
Active Comparator group
Description:
women who received GnRH antagonist
Treatment:
Drug: Cetrorelix
Control
No Intervention group
Description:
women who did not receive GnRH antagonist

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems